IL153593A0 - A pharmaceutical composition containing a soluble ctla4 mutant molecule - Google Patents

A pharmaceutical composition containing a soluble ctla4 mutant molecule

Info

Publication number
IL153593A0
IL153593A0 IL15359301A IL15359301A IL153593A0 IL 153593 A0 IL153593 A0 IL 153593A0 IL 15359301 A IL15359301 A IL 15359301A IL 15359301 A IL15359301 A IL 15359301A IL 153593 A0 IL153593 A0 IL 153593A0
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
composition containing
soluble ctla4
mutant molecule
ctla4 mutant
Prior art date
Application number
IL15359301A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22804919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL153593(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL153593A0 publication Critical patent/IL153593A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
IL15359301A 2000-07-03 2001-07-02 A pharmaceutical composition containing a soluble ctla4 mutant molecule IL153593A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21591300P 2000-07-03 2000-07-03
PCT/US2001/021204 WO2002002638A2 (en) 2000-07-03 2001-07-02 Methods for treating rheumatic diseases using a soluble ctla4 molecule

Publications (1)

Publication Number Publication Date
IL153593A0 true IL153593A0 (en) 2003-07-06

Family

ID=22804919

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15359301A IL153593A0 (en) 2000-07-03 2001-07-02 A pharmaceutical composition containing a soluble ctla4 mutant molecule
IL153593A IL153593A (en) 2000-07-03 2002-12-23 Pharmaceutical composition containing a soluble ctla4 mutant molecule

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153593A IL153593A (en) 2000-07-03 2002-12-23 Pharmaceutical composition containing a soluble ctla4 mutant molecule

Country Status (39)

Country Link
US (1) US7455835B2 (xx)
EP (4) EP1372696B1 (xx)
JP (1) JP2004517806A (xx)
KR (3) KR20030017606A (xx)
CN (1) CN1318086C (xx)
AR (2) AR035037A1 (xx)
AT (1) ATE401909T1 (xx)
AU (2) AU2001273174B2 (xx)
BG (2) BG66024B1 (xx)
BR (1) BR0112104A (xx)
CA (2) CA2413190C (xx)
CY (3) CY1109786T1 (xx)
CZ (1) CZ303959B6 (xx)
DE (1) DE60135029D1 (xx)
DK (2) DK1935427T3 (xx)
EE (1) EE05378B1 (xx)
ES (2) ES2667203T3 (xx)
HK (1) HK1058486A1 (xx)
HR (1) HRP20030071B1 (xx)
HU (3) HU227669B1 (xx)
IL (2) IL153593A0 (xx)
IS (1) IS2834B (xx)
LT (2) LT1935427T (xx)
LV (1) LV12993B (xx)
MX (1) MXPA02012603A (xx)
MY (1) MY137552A (xx)
NO (3) NO20026264L (xx)
PE (1) PE20020772A1 (xx)
PL (2) PL212205B1 (xx)
PT (2) PT1372696E (xx)
RS (1) RS50811B (xx)
RU (1) RU2287340C2 (xx)
SI (3) SI1935427T1 (xx)
SK (1) SK287940B6 (xx)
TR (1) TR201807700T4 (xx)
TW (2) TWI322153B (xx)
UY (1) UY26815A1 (xx)
WO (1) WO2002002638A2 (xx)
ZA (1) ZA200210058B (xx)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
UY26723A1 (es) * 2000-05-26 2001-12-28 Bristol Myers Squibb Co Moléculas mutantes de ctla4 solubles y usos de las mismas
KR20030007899A (ko) * 2000-06-09 2003-01-23 브리스톨-마이어스스퀴브컴파니 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
TWI322153B (en) * 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
WO2003088991A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
WO2004058800A2 (en) * 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
BRPI0413326A (pt) * 2003-08-04 2006-10-10 Bristol Myers Squibb Co métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PL2253644T3 (pl) * 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
CN101822820A (zh) * 2005-12-20 2010-09-08 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
AU2014250683B2 (en) * 2007-11-01 2015-11-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
EP2612868B1 (en) * 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en) * 2007-11-01 2014-08-28 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
EP2459251B1 (en) 2009-07-30 2014-03-12 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN102030828B (zh) * 2009-09-25 2014-10-29 上海抗体药物国家工程研究中心有限公司 一种高亲和力的CTLA4-Ig融合蛋白突变体
CN103038251B (zh) * 2010-02-19 2016-08-17 Xencor公司 新颖ctla4-ig免疫粘附素
KR20130049775A (ko) 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ｃｔｌａ４ 단백질 및 이의 용도
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
CA2810631A1 (en) 2010-09-08 2012-03-15 Yeda Research And Development Co. Ltd. An immunosuppressive drug combination for a stable and long term engraftment
CN103282047B (zh) 2010-09-08 2016-08-24 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
WO2013010537A1 (en) * 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
CN103930130B (zh) 2011-09-08 2016-07-06 耶达研究及发展有限公司 抗第三方中央型记忆t细胞、其产生方法以及其在移植和疾病治疗中的应用
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
MX2015000237A (es) 2012-06-27 2015-08-14 Orban Biotech Llc Proteinas de fusion ctla4 para el tratamiento de la diabetes.
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
WO2014151230A2 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
AU2015249656A1 (en) * 2014-04-25 2016-11-03 Bristol-Myers Squibb Company Use of CTLA4 compound for achieving drug-free remission in subjects with early RA
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
CA2991690A1 (en) 2015-07-16 2017-01-19 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory t cells and use of same in immunotherapy
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
MA50360A (fr) 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
KR20200085777A (ko) 2017-10-18 2020-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
EP3765065A2 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175384A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3765064A1 (en) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
AU2020208909A1 (en) 2019-01-15 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy
WO2023112992A1 (ja) * 2021-12-16 2023-06-22 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644792A (en) * 1899-09-14 1900-03-06 Stanhope Boal Heater.
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3424893A1 (de) 1984-07-06 1986-02-06 Agfa-Gevaert Ag, 5090 Leverkusen Photographisches silberhalogenidaufzeichnungsmaterial
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5624823A (en) * 1991-11-22 1997-04-29 The General Hospital Corporation DNA encoding procine interleukin-10
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
JPH07508711A (ja) 1992-04-07 1995-09-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｃｄ２８経路免疫調節
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
ATE293686T1 (de) 1993-06-04 2005-05-15 Us Navy Verfahren zur selektiven stimulierung der t- zellproliferation.
AU7107794A (en) 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
WO1995006481A1 (en) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Methods for inducing antigen-specific t cell tolerance
RU2141318C1 (ru) * 1993-12-01 1999-11-20 Санкио Компани Лимитед Ингибитор образования воспалительного цитокина, средство для профилактики и лечения воспалительных заболеваний пищеварительного тракта и синдрома бехчета, способ профилактики и лечения воспалительных заболеваний и язвенного колита
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
AU1333195A (en) 1994-06-03 1996-01-04 Dana-Farber Cancer Institute Methods for selectively stimulating proliferation of t cells
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
AU2701895A (en) 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
US5634055A (en) * 1994-09-27 1997-05-27 Bidplus, Inc. Method for selecting assignments
WO1996014865A1 (en) 1994-11-10 1996-05-23 Repligen Corporation Methods for inhibiting graft versus host disease in bone marrow transplantation
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5993800A (en) * 1995-06-05 1999-11-30 Bristol-Myers Squibb Company Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
JPH1067653A (ja) * 1996-06-17 1998-03-10 Eisai Co Ltd 関節疾患治療剤
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
CA2291338A1 (en) 1997-06-11 1998-12-17 Wisconsin Alumni Research Foundation Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
EP0947524A1 (en) * 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
PT1066060E (pt) * 1998-04-03 2003-12-31 Osiris Therapeutics Inc Celulas estaminais mesenquimais como imunossupressores
CA2333726A1 (en) * 1998-06-05 1999-12-09 Supergen, Inc. Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis
JP2000086519A (ja) * 1998-09-17 2000-03-28 Mitsui Chemicals Inc 抗リウマチ薬効果増強剤
IL126681A0 (en) 1998-10-21 1999-08-17 Opperbas Holding Bv Treatment of trauma-related conditions
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2001264936A1 (en) 2000-05-23 2001-12-03 Genaissance Pharmaceuticals, Inc. Haplotypes of the ctla4 gene
UY26723A1 (es) * 2000-05-26 2001-12-28 Bristol Myers Squibb Co Moléculas mutantes de ctla4 solubles y usos de las mismas
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
KR20030007899A (ko) * 2000-06-09 2003-01-23 브리스톨-마이어스스퀴브컴파니 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
TWI322153B (en) * 2000-07-03 2010-03-21 Bristol Myers Squibb Co Methods for treating rheumatic diseases using a soluble ctla4 molecule
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
PL204899B1 (pl) * 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4

Also Published As

Publication number Publication date
EP1372696B1 (en) 2008-07-23
SK17742002A3 (sk) 2004-11-03
HRP20030071A2 (en) 2005-02-28
CY2008017I1 (el) 2009-11-04
YU101102A (sh) 2006-01-16
HUS1000008I1 (hu) 2019-06-28
RU2287340C2 (ru) 2006-11-20
EP1935427A2 (en) 2008-06-25
HRP20030071B1 (hr) 2014-01-03
EP1935427A3 (en) 2011-05-25
CY1120577T1 (el) 2019-07-10
US7455835B2 (en) 2008-11-25
WO2002002638A3 (en) 2003-10-30
KR20080075564A (ko) 2008-08-18
LT2003002A (en) 2003-07-25
SK287940B6 (sk) 2012-05-03
ATE401909T1 (de) 2008-08-15
BR0112104A (pt) 2004-07-20
KR100895552B1 (ko) 2009-04-29
TW200902546A (en) 2009-01-16
CZ303959B6 (cs) 2013-07-17
EP3384924A1 (en) 2018-10-10
CN1477968A (zh) 2004-02-25
HUP0301727A2 (hu) 2003-09-29
TWI311564B (en) 2009-07-01
DK1372696T3 (da) 2008-11-03
KR100864120B1 (ko) 2008-10-16
SI1935427T1 (en) 2018-05-31
HK1058486A1 (en) 2004-05-21
AU2001273174C1 (en) 2002-01-14
PT1372696E (pt) 2008-10-24
BG66454B1 (bg) 2014-10-31
CZ20024261A3 (cs) 2004-08-18
LT1935427T (lt) 2018-05-10
SI1372696T1 (sl) 2008-12-31
EP2281568A2 (en) 2011-02-09
KR20080025216A (ko) 2008-03-19
SI21078A (sl) 2003-06-30
EE05378B1 (et) 2011-02-15
ES2310557T3 (es) 2009-01-16
CA2413190A1 (en) 2002-01-10
NO20100579L (no) 2003-02-19
AR035037A1 (es) 2004-04-14
PE20020772A1 (es) 2002-09-06
US20030083246A1 (en) 2003-05-01
NO20100580L (no) 2003-02-19
LT5063B (lt) 2003-11-25
EP1372696A2 (en) 2004-01-02
KR20030017606A (ko) 2003-03-03
DK1935427T3 (en) 2018-06-06
PT1935427T (pt) 2018-05-16
CY1109786T1 (el) 2011-04-06
WO2002002638A2 (en) 2002-01-10
DE60135029D1 (de) 2008-09-04
IS2834B (xx) 2013-05-15
TR201807700T4 (tr) 2018-06-21
CN1318086C (zh) 2007-05-30
AU7317401A (en) 2002-01-14
LV12993B (en) 2003-10-20
MXPA02012603A (es) 2003-05-14
CY2008017I2 (el) 2016-08-31
EP1935427B1 (en) 2018-03-07
JP2004517806A (ja) 2004-06-17
PL207534B1 (pl) 2010-12-31
AU2001273174B2 (en) 2006-05-18
HUP0301727A3 (en) 2008-08-28
IL153593A (en) 2009-09-01
BG107362A (bg) 2003-09-30
MY137552A (en) 2009-02-27
CA2413190C (en) 2009-04-07
CA2630062A1 (en) 2002-01-10
BG66024B1 (bg) 2010-11-30
EE200300004A (et) 2004-10-15
ZA200210058B (en) 2005-02-23
HU227669B1 (en) 2011-11-28
CA2630062C (en) 2014-10-14
RS50811B (sr) 2010-08-31
IS6667A (is) 2003-01-02
TWI322153B (en) 2010-03-21
ES2667203T3 (es) 2018-05-10
PL365942A1 (en) 2005-01-24
HU226847B1 (en) 2009-12-28
EP2281568A3 (en) 2013-04-24
NO20026264L (no) 2003-02-19
PL212205B1 (pl) 2012-08-31
BG110611A (bg) 2010-05-31
NO20026264D0 (no) 2002-12-27
UY26815A1 (es) 2002-01-31
AR066511A2 (es) 2009-08-26

Similar Documents

Publication Publication Date Title
IL153593A0 (en) A pharmaceutical composition containing a soluble ctla4 mutant molecule
IL213240A (en) Pharmacy composition containing poly-fluorescein conjugate
AU781269C (en) Pharmaceutical compositions
EG24357A (en) New Pharmaceutical composition
IL150549A0 (en) Pharmaceutical parenteral composition containing a biphosphonate
IL152659A0 (en) Pharmaceutical composition
HK1075889A1 (en) Pharmaceutical composition
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
AU2001250420A1 (en) Pharmaceutical compositions
HUP0204555A3 (en) Pharmaceutical composition
AU2001274307A1 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
AU2001271037A1 (en) Pharmaceutical compositions containing dds compounds
AU8576801A (en) Pharmaceutical compositions
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
IL154238A0 (en) Pharmaceutical composition
AU2001273919A1 (en) Pharmaceutical compositions
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU4085201A (en) Pharmaceutical composition
AU2001278705A1 (en) Pharmaceutical composition
AU3586401A (en) Pharmaceutical composition
AU2001285737A1 (en) Pharmaceutical compositions
GB0002691D0 (en) Pharmaceutical composition
GB0101094D0 (en) Pharmaceutical composition
AUPQ875300A0 (en) A pharmaceutical composition